Wednesday, July 8, 2026

Patent intelligence · US

US 8338173

Preparation of antigen-presenting human γδ T cells and use in immunotherapy

granted A61KA61K2035/124A61K2239/57A61K39/04
Status granted
Linked drugs 4
Pipeline programs 6
Years to expiry 6
Applicant portfolio 69
Patent details — US 8338173
Jurisdiction
US
Status
granted
Grant date
Dec 25, 2012
Expiration
Dec 20, 2032
Claims
20
CPC classes
A61K, A61K2035/124, A61K2239/57, A61K39/04
View on Google Patents ↗

Quick answer

US 8338173 (Preparation of antigen-presenting human γδ T cells and use in immunotherapy) is held by University College Cardiff Consultants Limited. Status: granted. Granted Dec 25, 2012. Expires Dec 20, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K2035/124, A61K2239/57, A61K39/04, A61K40/11, A61K40/13

More from University College Cardiff Consultants Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12383540

    Compounds that modulates AMPA receptor function

    University College Cardiff Consultants Limited · Expires Aug 7, 2045

    granted
  2. US 12318418

    Modified adenoviruses

    University College Cardiff Consultants Limited · Expires May 29, 2045

    granted
  3. US 12263173

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Expires Mar 27, 2045

    granted
  4. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Expires Nov 14, 2044

    granted
  5. US 12053513

    Cancer-specific T-cell receptors

    University College Cardiff Consultants Limited · Expires Aug 1, 2044

    granted
  6. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Cardiff Oncology, Inc. · Expires Apr 11, 2044

    granted
  7. US 11850264

    Gamma delta T-cell receptor and its ligand

    University College Cardiff Consultants Limited · Expires Dec 21, 2043

    granted
  8. US 11725039

    α/β t-cell receptor and methods of using it

    University College Cardiff Consultants Limited · Expires Aug 10, 2043

    granted

Frequently asked questions

What is US patent 8338173?

US 8338173 (Preparation of antigen-presenting human γδ T cells and use in immunotherapy) is held by University College Cardiff Consultants Limited. Status: granted. Granted Dec 25, 2012. Expires Dec 20, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8338173?

University College Cardiff Consultants Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.

When does US 8338173 expire?

Our index shows an expiration date of Dec 20, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.